#VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: metastatic colorectal cancer
Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer
1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events ...
#VisualAbstract: Nivolumab Plus Ipilimumab Increased Pro-gression-Free Survival in Microsatellite-In-stability-High Metastatic Colorectal Cancer
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Fluorouracil, leucovorin and irinotecan plus panitumumab for the treatment of metastatic colorectal cancer
1. An intermittent strategy with fluorouracil, leucovorin and irinotecan (FOLFIRI) plus panitumumab (PAN) following induction was feasible, showed reduced toxicity ...
Liver transplantation plus chemotherapy improves survival in patients with unresectable colorectal liver metastases
1. 5-year survival was significantly greater in the liver transplantation plus chemotherapy group compared to chemotherapy alone. 2. Serious adverse ...
Fruquintinib significantly improves survival in patients with refractory metastatic colorectal cancer
1. Overall survival was significantly greater in the fruquintinib group versus placebo. 2. The majority of adverse events were mild-to-moderate ...
#VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
Overall tumour response to monotherapy treatment with adagrasib was 23% 46% in combination with cetuximab. Median progression-free survival was 5.6 ...
Addition of atezolizumab to FOLFOXIRI and bevacizumab led to limited increase in survival in metastatic colorectal cancer
1. The median progression-free survival was marginally increased in the atezolizumab group. 2. Adverse events of grades 3 and 4 ...